Viewing Study NCT00002258

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:12 AM
Ignite Modification Date: 2026-02-22 @ 9:38 AM
Study NCT ID: NCT00002258
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-11-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia
Sponsor: Sandoz
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV Infections View
None Cytopenias View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Interleukin-3 View
None Recombinant Proteins View
None Leukopenia View
None Acquired Immunodeficiency Syndrome View
None AIDS-Related Complex View
None Thrombocytopenia View